G lutamine (Gln) is the most abundant free amino acid in the extracellular and intracellular compartments, contributing to more than 50% of the body's free amino acid pool (1) . Gln is involved in a wide variety of metabolic and synthetic biochemical processes and supports rapidly proliferating cells, such as lymphocytes and enterocytes (2) , and acts as nitrogen and ammonium carrier to the liver and kidney (1) . In conditions of excessive organ/tissue demand of Gln during episodes of sepsis following trauma, major surgery, and other catabolic stress situations, endogenous Gln production may not be sufficient to meet the increased requirements (3) , and up to 50% of Gln depletion might be observed (4, 5) . In addition, Gln depletion has been associated with poor prognosis in hypercatabolic situations such as burn injury (6) .
Gln limits intestinal permeability in experimental models in animals (7) and reduces gut atrophy (8, 9) . It also preserves intestinal and extraintestinal immunoglobulin A levels (10) and decreases intestinal proinflammatory cytokine production (11) . In humans, Gln supplementation reduced clinical infections after bone-marrow transplantation (12) and maintained gut integrity during total parenteral nutrition (TPN) (13) . A recent meta-analysis showed that Gln supplementation reduces infectious morbidity and length of hospital stay in surgical patients, but the effects of Gln on clinical outcome and mortality rate for critically ill patients were less clear because of the more limited number of studies (14) .
In this multicenter study, we evaluated the effect of Gln dipeptide-supplemented TPN on clinical outcome for 114 critically ill patients.
PATIENTS AND METHODS
The study was approved by the ethics committee of Haute-Normandie, France. All patients or their closest relative gave written informed consent. This was a controlled, randomized, double-blind, multicenter trial.
Patients. Eligible patients were at least 18 yrs old, admitted to the intensive care unit (ICU) between January 1996 and December 2000, required TPN for at least 5 days because of contraindication for or failure of enteral nutrition, and had a therapeutic intervention scoring system (TISS) score of Ն16 and an injury severity score of Ն10 (for multiple trauma patients) or a simplified acute physiology score II (SAPS II) of Ն22 (for patients with complications after surgery or pancreatitis). Patients meeting inclusion criteria were included consecutively in each center. The exclusion criteria were malnutrition or severe obesity (body mass index, Ͻ18.5 or Ͼ35 kg·m Ϫ2 ), pregnancy or lactation, persistent hemodynamic failure (systolic blood pressure, Ͻ80 mm Hg), renal insufficiency (serum creatinine level, Ն250 mol·L Ϫ1 ), hepatic failure (prothrombin time, Ͼ23.7 secs [normal range, 12.7-14.5 secs], and/or hepatic encephalopathy), severe or uncontrolled sepsis, persistent metabolic acidosis, hypertriglyceridemia (Ͼ3 N), head trauma (Glasgow score Ͻ5 at admission), steroid therapy (Ͼ0.3 mg·kg Ϫ1 ·d Ϫ1 ), immunosuppressive therapy or constitutive immune deficiency, human immunodeficiency virus infection, enrollment in another study, and life expectancy Ͻ7 days.
Treatment Assignment. The study medications, alanyl-glutamine (Ala-Gln) and alanine (Ala) ϩ proline (Pro), were randomly assigned to the patient numbers at the study sites and were randomized on a 1:1 basis, by means of a computer program (SAS, Chicago). The randomization envelopes were held by the pharmacist and were assigned in strict chronological ascending order within each treatment group. The TPN solution was freshly prepared in the hospital pharmacy and labeled with patient and study numbers, the name of the investigator, and the date of the preparation. Ala-Gln and Ala ϩ Pro containing TPN were labeled identically and the two solutions were indistinguishable. All patients, investigators, and coworkers were unaware of treatment allocation and remained blinded to the treatment allocation until the final statistical evaluation was completed.
Composition of Regimens. Secondary Variables. ICU and total hospital length of stay (LOS) and 6-month mortality rate were also prospectively recorded. Transthyretin (TTR), retinol binding protein (RBP), albumin, ␣-1 acid glycoprotein (AGP) and Creactive protein (CRP) were measured in serum by nephelometry (Image Analyser, Beckman-Coulter, USA) in a centralized center by the same investigator (L.C.). Then, the prognostic inflammatory and nutritional index, defined as [AGP (mg·L
, was calculated. The 24-hr urine specimens were collected and the daily diuresis was recorded and noted. The pyroluminescence technique (Antek, USA) was used to assess the urinary nitrogen content, in order to calculate the apparent nitrogen balance (nitrogen intravenous infusion Ϫ urinary nitrogen). Urinary 3-methylhistidine was measured by ion exchange chromatography (Hitachi, Japan), and creatinine concentrations were determined by routine method. Plasma amino acids profiles were analyzed by ion exchange (Biotronik LC3000, Eppendorf) in a centralized center by the same investigator (B.H.). Routine analyses (hematology, chemistry, and immunology) were performed in each center. Severe hyperglycemia was defined as a blood glucose level Ͼ12 mmol/L.
Statistical Analysis. A power size calculation was based on the results of the previous clinical trial available at the time when the protocol was written (17) ; this study documented a reduction of ICU costs estimated from TISS score. On the basis of the mean value of the daily TISS scores in both groups of this study (30.7 Ϯ 5.6 vs. 34.2 Ϯ 8.1 in the Gln and control groups, respectively), the calculated sample size reached the number of 102 evaluable patients (2 ϫ 51), with a risk ␣ equal to 5% and for a power of 1-␤ equal to 90%. To take into account some dropouts, the protocol was planned initially to include 110 patients. Finally, 114 patients were included. Statistical analysis was performed by intention to treat (ITT) and per protocol with use of BMDP program 7.0 (University of California Press, Berkeley, CA). Patients with Ͻ4 days of TPN were not eligible for efficacy evaluation. For quantitative variables, Student's t-test was performed if the criteria of normal distribution in each group and comparable variances between both groups were met. In other cases, the nonparametric Mann-Whitney test was used. For repeated assessments during the study period, repeated-measures analysis of variance (ANOVA) was used. Qualitative variables were compared with chi-square tests and Yates correction if necessary. These tests were two-sided, with an ␣ risk ϭ 5%. The statistical analysis focused on the criteria relevant to the primary efficacy, with a p value Ͻ .05. For secondary efficacy and tolerance outcomes, no correction for multiple testing was performed. Thus, results mainly have a descriptive value and p values should be considered as indicative.
RESULTS
Between January 1996 and December 2000, 114 patients at 16 centers with multiple trauma (n ϭ 38), complications after surgery (n ϭ 65: peritonitis, 19; digestive resection for cancer, 28; other resection, 18), or pancreatitis (n ϭ 11) were enrolled in the study. They were randomized to the Ala-Gln group (n ϭ 58) or control group (n ϭ 56) as shown in Figure 1 . On admission, there were no difference between groups according to the demographic data, illness severity scores (Table 1) , and metabolic and nutritional parameters ( Table 2 ). The numbers of diabetic patients (two vs. six; p ϭ .129) and alcoholic patients (4 vs. 3; p ϭ .732), respectively, included in the AlaGln and control groups were not significantly different. Ten patients (6, Ala-Gln; 4, control) received Ͻ4 days of TPN because of adverse events or other reasons, as described in Figure 1 . Thus, analysis by ITT was performed for 114 patients (58 vs. 56) and per protocol analysis was done for 104 patients (52 vs. 52). The supply of amino acids (1.36 Ϯ 0.3 vs. 1.38 Ϯ 0.3 g·kg Ϫ1 ·d Ϫ1 ), carbohydrates, and lipids (total calories, 33.4 Ϯ 5.5 vs. 33.6 Ϯ 5.6 kcal·kg Ϫ1 ·d Ϫ1 ) was in accordance with the study design and not different between the groups. There was also no difference in the duration of TPN (6.6 Ϯ 2.1 vs. 6.9 Ϯ 2.1 days for Ala-Gln and control group, respectively).
Clinical Outcome. The proportion of patients with a complicated clinical outcome was significantly lower among those receiving Ala-Gln than among control patients (Table 3) : 41% (confidence interval [CI], 29%-54%) vs. 61% (CI, 48%-74%) (p Ͻ .05) in ITT analysis and 39% (CI, 25%-52%) vs. 64% (CI, 50%-77%) (p Ͻ .02) in per protocol analysis. Patients receiving Ala-Gln had fewer nosocomial infections (p ϭ .06 in ITT and p Ͻ .02 in per protocol analysis). The number of episodes of nosocomial infection per patient was lower in the Ala-Glntreated group than in the control group (Table 3) . Wound healing alterations and death during the study period were not significantly different between the two groups ( Table 3 ). The 6-month outcome was checked for all included patients by means of hospital charts or contact with the practitioner. The number of deaths over 6 months was not different between groups (Table 3) .
The decrease in nosocomial infections in patients receiving Ala-Gln was related mainly to a decrease in the incidence of pneumonia (Table 4 ; p Ͻ .05). The overall incidence of other infections (surgical wound, septic shock, sepsis, urinary or intravenous catheter infection) amounted to 16 and 21 episodes, respectively, in the AlaGln and control groups (not significant). For pneumonia, each episode corresponded to a single patient. Two patients in the Ala-Gln group and six patients in the control group had two different types of infectious episodes (e.g., pneumonia and wound infection; pneumonia and septic shock). The number of adverse events per patient was significantly lower in the Ala-Gln group (2.0 vs. 2.8; p Ͻ .01).
An indicative post hoc observation of each subgroup (multiple trauma, complications after surgery, and pancreatitis) showed that nosocomial infections were markedly reduced in multiple trauma patients receiving Ala-Gln (8 of 17 The days of mechanical ventilation were prospectively recorded for each patient to calculate the TISS score; the median number (range) of ventilation days after inclusion was 2 (0 -148) in the AlaGln group and 5 (0 -133) in the Ala-Pro group. Because this parameter was not included a priori in the protocol, the statistical analysis should be considered only indicative (p ϭ .853).
On day 1, TISS score was comparable between the two groups ( Table 1) . Moreover, TISS score varied between each subgroup. Indeed, the highest TISS scores were recorded for multiple-trauma patients. In the Ala-Gln and control groups, the TISS value decreased over time to 20.8 (6.5-43.5) and 20.4 (9.1-45.5), respectively (not significant).
The median LOS in the ICU and hospital did not differ between the groups, including all patients and only survivors ( Table 3 ). The 6-month outcome for patients receiving at least 4 days of TPN was not altered (Table 3) .
Metabolic and Nutritional Parameters. Metabolic disorders were the most commonly reported adverse events (Table  4) . Hyperglycemia (Ͼ10 mmol/L) was re- ported Table 4 . In both groups, CRP level decreased, whereas TTR and RBP increased over time ( Table 2) (Table 2) . Total lymphocyte and CD4 and CD8 subpopulation counts showed a comparable increase over days in both groups. Nitrogen balance was more negative in control patients than in Ala-Glnsupplemented patients, but the difference did not reach significance (Table 2 ; p ϭ .18). Cumulative nitrogen was also not significantly different between the Ala-Gln and control groups (Ϫ1.74 vs. Ϫ1.97 g). However, the 3-methylhistidine/creatinine ratio remained stable in the Ala-Gln group but decreased in the control group (Table 2 ; p Ͻ .05).
Plasma amino acid concentrations are displayed in Table 2 . Glutamine plasma level increased about 40% in patients receiving Ala-Gln. However, on day 6, Gln plasma levels were not significantly different between groups. Total plasma amino acids increased in both groups but more markedly in the control group (p Ͻ .01), mainly in relation to the plasma accumulation of proline (p Ͻ .01). 
; CRP, C-reactive protein; TTR, transthyretine; RBP, retinol binding protein; 3-MH/creatinine, 3-methylhistidine/creatinine ratio; ND, not determined.
Statistical comparisons were done with use of repeated-measures analysis of variance. 
DISCUSSION
In this multicenter, prospective, double-blind trial, Gln dipeptide-supplemented TPN improved complicated clinical outcome and metabolic tolerance in critically ill patients. The two groups had similar demographic characteristics and severity of illness scores at inclusion. The complication rate in the control group was high and in accordance with previously published studies (14) . Multiple trauma patients randomized to receive Ala-Gln presented with somewhat higher injury severity scores (median, 43.5 vs. 39.0) than control patients, indicating that illness severity may have been greater in these patients; despite this, Ala-Gln-treated trauma patients clearly benefit from Gln supplementation. The effects of Gln, given as Ala-Gln dipeptide, were compared with those of a mixture of Ala ϩ Pro, since this control mixture allows an easy isonitrogenous, wellblinded control and both amino acids are considered nonessential and nontoxic; thus, the composition of the control solution should not have favored the observation of the efficacy of Ala-Gln. The rate of dropouts (10 of 114 eligible randomized patients) was low. Thus, the results of the per protocol analysis are well in agreement with those of the ITT analysis. Although the duration of treatment was slightly shorter in the Ala-Gln group than in the control group (6.6 vs. 6.9 days, respectively), this minor difference is unlikely to have contributed to the difference in complicated outcome, since most of the serious complications occurred within the first 5 days of treatment.
Ala-Gln-supplemented TPN was associated in the present study with a lower incidence of infectious events. This result is in accordance with the reduction of infectious events observed after administration of Gln-enriched enteral nutrition to trauma patients (5) and after parenteral supplementation with Gln in severely burned, enterally fed patients (15) . Parenteral Gln was also beneficial in patients with secondary peritonitis (16) . In critically ill patients receiving Glnsupplemented TPN, Griffiths et al. (17) observed no significant reduction in the number of infectious complications, but they later reported that the severity and the in-ICU death rate linked to infectious complications was reduced among Glntreated patients (18) . In a recent metaanalysis (14) , the risk ratio of Gln effect on infectious complications in critically ill patients was 0.80 (95% CI, 0.64 -1.00), which only approached statistical significance. Thus, the present study supports that Gln-enriched nutrition reduces infectious complications in critically ill patients. This reduction of infectious complications corresponded mainly to a lower incidence of pneumonia in Ala-Glntreated patients, as previously reported with use of Gln-enriched enteral nutrition (5) . The present study is the first, to our knowledge, to report an effect of Glnsupplemented parenteral nutrition on pneumonia incidence. We observed a trend toward decreased duration of ventilation in the Ala-Gln group in the present study (2 days, vs. 5 days in the control group). Although this did not reach statistical significance, this reduced ventilation could have favored clinical outcome.
Indeed, a recent study (19) showed that risk factors for ventilator-associated pneumonia in trauma patients include the duration of intubation (risk ratio, 1.06; CI, 1.01-1.17). On the other hand, the tendency toward a reduction in need for ventilation among patients receiving Ala-Gln may reflect an early beneficial effect of Gln on overall recovery, which is reflected by a reduced incidence of nosocomial pneumonia. However, the present study does not allow a clear determination of causal relationship between ventilation and infection. The data available from the study did not allow evaluating the consequence of improved outcome in terms of number of days of antibiotic therapy.
We did not observe any difference in mortality during the study period and in the ICU or hospital LOS. Other trials evaluating Gln-supplemented parenteral nutrition revealed a significant reduction in mortality after Gln supplementation (15, 17, 20) or a trend toward a reduction (21) . In the meta-analysis cited above, the risk ratio of the effect of Gln-enriched parenteral nutrition on mortality was 0.71 (95% CI, 0.51-0.99) (14) . The fact that no effect on early and 6-month death rate was observed in our study may reflect differences in the populations studied. Although no statistical difference was observed for the overall mortality, deaths were caused by infectious vs. noninfectious complications in six vs. three patients in the control group, whereas an opposite pattern (four vs. seven) was observed in the Ala-Gln-treated group. This suggests that Gln treatment may reduce the severity of infectious complications, as previously reported (18) , in addition to reducing the overall incidence of infectious complications. In the present study, Gln-enriched TPN had no significant effect on the ICU or hospital LOS, in accor- dance with other studies of hospital LOS for critically ill patients (14) . This reflects the multifactorial determinants of LOS in ICU units and hospitals, among which pneumonia may be only one factor. Other data on the influence of Gln supplementation on ICU LOS are still limited (20) .
In the present study, Gln supplementation induced a decrease of hyperglycemic events, which was not related to a different number of diabetic patients at inclusion (p ϭ .416), and thus raises the question of a specific effect of Gln on insulin sensitivity. Hyperglycemia related to insulin resistance is common in critically ill patients, and it has been reported that pronounced hyperglycemia may increase the risk of complications in such patients (22) , as in patients with diabetes (23) . At the time the study was started, a cut-off level of 10 mmol glucose per liter was usually tolerated in most ICU units. In contrast, in a recent randomized study, intensive insulin therapy with tight glycemic control decreased mortality and morbidity among ICU patients (24) , but the mechanisms of action of this beneficial effect remain debated. Insulin by itself or the reduction of hyperglycemia, or both, may contribute to the clinical effect (22) . Studies in healthy controls indicate that enteral infusion of Gln increases insulin level (25, 26) , but data on the effects of Gln on insulin resistance are still limited. Supplementation with Gln of obese mice resulted in persistent reductions in both plasma glucose and insulin levels (27) . In dogs, Gln infusion markedly increased whole-body glucose utilization, mainly muscular and hepatic, and also increased whole-body glucose production to some extent (28) . In addition, parenteral Ala-Gln administration attenuated insulin resistance in multiple trauma patients (29) . Nevertheless, the present study did not address specifically the level of insulin resistance in the patients included. Further investigations should be done to determine whether Gln is beneficial as an adjuvant in clinical situations associated with insulin resistance.
Several other mechanisms possibly explaining the effects of Gln deserve discussion. The improvement of clinical outcome could be explained by the influence of Gln on intestinal and immune function. Indeed, Gln decreased intestinal permeability in stressed patients (13, 30, 31) . Experimental studies report that Gln modulated inflammatory cytokine production by gut mucosa, decreasing proinflammatory cytokines such as interleukin 8 (11, 32) or increasing antiinflammatory cytokines such as interleukin 10 (33, 34) . In addition, Gln maintained intestinal and pulmonary IgA levels in rats (32, 33) . Gln also modulated heat-shock protein expression (34, 35) and improved intestinal protein metabolism (26, 36) . In addition, Gln maintained or restored immune defenses (37) (38) (39) and restored plasma Gln concentrations (20, 40, 41) . Finally, Gln may improve nitrogen balance (42) . In the present study, difference in nitrogen balance failed to reach significance, likely because of the large range of stress in studied patients. Gln supplementation did not affect myofibrillar proteolysis, but it decreased in control patients; this may reflect an enhanced protein turnover rate in Gln-treated patients, with proteolysis providing amino acid for protein synthesis in remote organs such as the gut (26), but these parameters were not assessed in the present study.
According to its design, this study documented the beneficial effects of Ala-Glnsupplemented parenteral nutrition in severely ill ICU patients requiring parenteral nutrition. Recently, several other investigators also reported the benefits of Glnenriched diets in patients able to be fed enterally (43, 44) . Thus, Gln appears to be a beneficial supplement for ICU patients, whatever the route they can be fed according to their clinical status.
CONCLUSIONS
In conclusion, we have shown that Gln dipeptide-supplemented TPN reduces the clinical complications of critically ill patients, mainly through a lower incidence of pneumonia and better metabolic tolerance. These findings strengthen the data obtained previously for ICU patients (14) and together form a strong rationale for the use of Gln-supplemented regimens for ICU patients. 
